29 related articles for article (PubMed ID: 10600273)
1. Tale of two systems: the intertwining duality of fibrinolysis and lipoprotein metabolism.
Dai W; Castleberry M; Zheng Z
J Thromb Haemost; 2023 Oct; 21(10):2679-2696. PubMed ID: 37579878
[TBL] [Abstract][Full Text] [Related]
2. A counterview of 'An investigation of the false discovery rate and the misinterpretation of p-values' by Colquhoun (2014).
Loiselle D; Ramchandra R
R Soc Open Sci; 2015 Aug; 2(8):150217. PubMed ID: 26361549
[No Abstract] [Full Text] [Related]
3. Beneficial effects of L- and N-type calcium channel blocker on glucose and lipid metabolism and renal function in patients with hypertension and type II diabetes mellitus.
Masuda T; Ogura MN; Moriya T; Takahira N; Matsumoto T; Kutsuna T; Hara M; Aiba N; Noda C; Izumi T
Cardiovasc Ther; 2011 Feb; 29(1):46-53. PubMed ID: 20337636
[TBL] [Abstract][Full Text] [Related]
4. Dihydropyridine calcium antagonists increase fibrinolytic activity: a systematic review.
Vergouwen MD; Vermeulen M; de Haan RJ; Levi M; Roos YB
J Cereb Blood Flow Metab; 2007 Jul; 27(7):1293-308. PubMed ID: 17191079
[TBL] [Abstract][Full Text] [Related]
5. INFLUENCE OF BASELINE VALUES ON LIPIDS, LIPOPROTEINS AND FIBRINOLYTIC PARAMETERS DURING TREATMENT OF HYPERTENSION WITH CILNIDIPINE.
Ahaneku JE; Sakata K; Urano T; Takada Y; Takada A
Pharmacol Res; 2000 Jan; 41(1):79-82. PubMed ID: 10712830
[TBL] [Abstract][Full Text] [Related]
6. Influence of baseline values on lipids, lipoproteins and fibrinolytic parameters during amlodipine treatment of hypertension in Japanese patients.
Ahaneku JE; Sakata K; Urano T; Takada Y; Takada A
Pharmacol Res; 2000 Jan; 41(1):75-9. PubMed ID: 10600272
[TBL] [Abstract][Full Text] [Related]
7. Effects of cilnidipine on lipids, lipoproteins and fibrinolytic system in hypertensive patients.
Ahaneku JE; Sakata K; Uranol T; Takada Y; Takada A
Drugs Exp Clin Res; 2000; 26(4):119-23. PubMed ID: 11109511
[TBL] [Abstract][Full Text] [Related]
8. INFLUENCE OF BASELINE VALUES ON LIPIDS, LIPOPROTEINS AND FIBRINOLYTIC PARAMETERS DURING AMLODIPINE TREATMENT OF HYPERTENSION IN JAPANESE PATIENTS.
Ahaneku JE; Sakata K; Urano T; Takada Y; Takada A
Pharmacol Res; 2000 Jan; 41(1):73-77. PubMed ID: 10712829
[TBL] [Abstract][Full Text] [Related]
9. Influence of baseline values on lipids and lipoprotein changes during amlodipine treatment of hypertension.
Ahaneku JE
Pharmacol Res; 1998 Sep; 38(3):179-82. PubMed ID: 9782067
[TBL] [Abstract][Full Text] [Related]
10. Influence of baseline values on lipids, lipoproteins and fibrinolytic parameters during treatment of hypertension with cilnidipine.
Ahaneku JE; Sakata K; Urano T; Takada Y; Takada A
Pharmacol Res; 2000 Jan; 41(1):81-4. PubMed ID: 10600273
[TBL] [Abstract][Full Text] [Related]
11. The efficacy and safety of cilnidipine on mild to moderate essential hypertension: a systematic review and meta-analysis of randomized controlled trials in Chinese patients.
Xu G; Wu H; Du B; Qin L
Cardiovasc Hematol Disord Drug Targets; 2012 Sep; 12(1):56-62. PubMed ID: 22746347
[TBL] [Abstract][Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
